Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1973 Apr;70(4):1169–1173. doi: 10.1073/pnas.70.4.1169

Discriminating Neoantigenic Differences Between Fibrinogen and Fibrin Derivatives

Edward F Plow 1, Thomas S Edgington 1
PMCID: PMC433450  PMID: 4123931

Abstract

Discrimination between the physiological cleavage fragments of fibrinogen and fibrin offers an approach to differentiation between fibrinogenolytic processes and fibrinolysis after coagulation. By use of the cleavage-associated neoantigen of fibrinogen (fg-Dneo) as a molecular marker, characteristic differences between the D regions of fibrinogen derivatives and fibrin derivatives can be demonstrated. The expression of fg-Dneo by X, Y, D:E complex, and D-fragments of fibrinogen or fibrin is shown to be quantitative and unitary. Characteristic differences between fg-Dneo sites present on fibrinogen cleavage fragments, as contrasted to fibrin cleavage fragments, are indicated by different competitive inhibition slopes, and appear to reflect differential binding affinity of selected anti-fg-Dneo antibodies for the specific molecular site. There is a linear relationship between the slope of quantitative competitive inhibition and the relative molar ratio of fibrinogen and fibrin derivatives. Identical immunochemical expressions are observed in vitro and in vivo, and support the thesis that cleavage in vivo is produced by plasmin. The differential immunochemical features of fg-Dneo expression may be the result of stable conformational and/or subtle structural differences between the D region of fibrinogen and fibrin cleavage fragments and suggest that precise changes in the D region are associated with the fibrin transition. These molecular features not only provide additional insight into the molecular immunology and structure of fibrinogen, but also appear to offer a new molecular approach to discrimination between fibrinogenolytic mechanisms as contrasted to fibrinolysis secondary to coagulation.

Keywords: disseminated intravascular coagulation, fibrinolysis, fibrinogenolysis, molecular immunology, neoantigens

Full text

PDF
1169

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASTRUP T. Fibrinolysis in the organism. Blood. 1956 Sep;11(9):781–806. [PubMed] [Google Scholar]
  2. Beller F. K., Maki M. Properties of fibrinogenolysis and fibrinolysis products in immune assays. Thromb Diath Haemorrh. 1967 Aug 15;18(1-2):114–132. [PubMed] [Google Scholar]
  3. Doolittle R. F., Schubert D., Schwartz S. A. Amino acid sequence studies on artiodactyl fibrinopeptides. I. Dromedary camel, mule deer, and cape buffalo. Arch Biochem Biophys. 1967 Feb;118(2):456–467. doi: 10.1016/0003-9861(67)90374-8. [DOI] [PubMed] [Google Scholar]
  4. Dudek G. A., Kloczewiak M., Budzyński A. Z., Latallo Z. S., Kopeć M. Characterisation and comparison of macromolecular end products of fibrinogen and fibrin proteolysis by plasmin. Biochim Biophys Acta. 1970 Jul 27;214(1):44–51. doi: 10.1016/0005-2795(70)90068-1. [DOI] [PubMed] [Google Scholar]
  5. EISEN H. N., SISKIND G. W. VARIATIONS IN AFFINITIES OF ANTIBODIES DURING THE IMMUNE RESPONSE. Biochemistry. 1964 Jul;3:996–1008. doi: 10.1021/bi00895a027. [DOI] [PubMed] [Google Scholar]
  6. Ekert H., Muntz R. H. Plasmin lysis of fibrinogen and fibrin and the antigenic properties of their degradation products. Br J Haematol. 1972 Jan;22(1):103–110. doi: 10.1111/j.1365-2141.1972.tb08791.x. [DOI] [PubMed] [Google Scholar]
  7. Marder V. J., Budzyński A. Z., James H. L. High molecular weight derivatives of human fibrinogen produced by plasmin. 3. Their NH2-terminal amino acids and comparison with the "NH2-terminal disulfide knot". J Biol Chem. 1972 Aug 10;247(15):4775–4781. [PubMed] [Google Scholar]
  8. Marder V. J., Matchett M. O., Sherry S. Detection of serum fibrinogen and fibrin degradation products. Comparison of six technics using purified products and application in clinical studies. Am J Med. 1971 Jul;51(1):71–82. doi: 10.1016/0002-9343(71)90325-1. [DOI] [PubMed] [Google Scholar]
  9. Marder V. J., Shulman N. R., Carroll W. R. The importance of intermediate degradation products of fibrinogen in fibrinolytic hemorrhage. Trans Assoc Am Physicians. 1967;80:156–167. [PubMed] [Google Scholar]
  10. Plow E. F., Hougie C., Edgington T. S. Neoantigenic expressions engendered by plasmin cleavage of fibrinogen. J Immunol. 1971 Nov;107(5):1496–1500. [PubMed] [Google Scholar]
  11. Plow E., Edgington T. S. Immunobiology of fibrinogen. Emergence of neoantigenic expressions during physiologic cleavage in vitro and in vivo. J Clin Invest. 1973 Feb;52(2):273–282. doi: 10.1172/JCI107183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Plow E., Edgington T. S. Molecular events responsible for modulation of neoantigenic expression: the cleavage-associated neoantigen of fibrinogen (blood coagulation-fibrinogen cleavage products-fibrinolysis-molecular conformation). Proc Natl Acad Sci U S A. 1972 Jan;69(1):208–212. doi: 10.1073/pnas.69.1.208. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES